Table 3.
Effect of Different Treatments on Renal Tissue TNF-Α, IL-6, TGF-Β1, Caspases 3 Activity and Apoptotic Index in the Studied Groups
| Control | Carboplatin | Carboplatin + Candesartan | Carboplatin + CoQ10 | Carboplatin + CMC | Carboplatin + Candesartan+ CoQ10 | F-value | df | |
|---|---|---|---|---|---|---|---|---|
| Tissue TNF-α (pg/ mg protein) | 40.5± 6.4 | 654.3±11.2a | 432.8±9.3b | 468.2±9.8b | 668.1±10.7 | 251.6±7.4bcd | 233.32 | 51 |
| Tissue IL-6 (pg/ mg protein) | 234.1±4.32 | 892.13±14.4 a | 597.2±9.1 b | 656.4±9.3 b | 899.62±12.3 | 390.3±6.4bcd | 144.17 | 51 |
| Tissue TGF-β1 (pg/ mg protein) | 21.83±1.07 | 73.6±4.2 a | 55.12±2.8b | 60.01±2.9 b | 71.5±4.5 | 41.3±1.3bcd | 99.07 | 51 |
| Tissue caspases 3 activity (nmol/mg protein/min) | 4.32±0.06 | 11.34±0.21 a | 7.81±0.09 b | 8.14±0.11 b | 10.94±0.19 | 6.67±0.08 bcd | 45.06 | 51 |
| Apoptotic index (%) | 4.11±0.05 | 8.44±0.12 a | 6.23±0.08 b | 6.56±0.09 b | 8.25±0.11 | 5.37±0.07 bcd | 48.53 | 51 |
Values were represented as mean ± S.E.M;
a
Significant compared to the control group (p-value less than 0.05);
b
Significant compared to carboplatin group (p-value less than 0.05);
c
Significant compared to carboplatin + candesartan group (p-value less than 0.05);
d
Significant compared to carboplatin + CoQ10 group (p-value less than 0.05).